bioMérieux increases its holding in Hybiome from 54% to 67%

06 June, 2019 bioMérieux, a world leader in the field of in vitro diagnostics, today announced an increase of its shareholding in Suzhou Hybiome Biomedical Engineering Co. Ltd. This announcement follows the earlier announcement of the acquisition of a majority stake in this company in November 2018. Founded in 2009 and located in Suzhou (China), Hybiome is specialized... Read more

bioMérieux acquires Invisible Sentinel, a US-based company specialized in food and beverage molecular testing

Marcy l’Étoile, France 07 February, 2019 bioMérieux, a global player in in vitro diagnostics and world leader in food microbiology testing, today announced the acquisition of Invisible Sentinel Inc. This company, based in Philadelphia (PA) develops, manufactures and markets innovative and user-friendly molecular diagnostic tools for the rapid, accurate and reliable detection of pathogens and spoilage organisms in... Read more

bioMérieux receives FDA clearance for BPA and BPN culture bottles used with BACT/ALERT® VIRTUO® for quality control testing of platelets

19 December, 2018 bioMérieux, a world leader in the field of in vitro diagnostics, announces that its culture bottles BACT/ALERT® BPA and BPN have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for quality control testing of leukocyte-reduced apheresis platelet (LRAP) units with the BACT/ALERT® VIRTUO® fully automated blood culture system. This innovative FDA cleared and CE marked... Read more

bioMérieux launches the BIOFIRE® FILMARRAY® Pneumonia Panels with FDA clearance and CE Marking

13 November, 2018 bioMérieux, a world leader in the field of in vitro diagnostics, today announced the Food and Drug Administration (FDA) 510(k) clearance of the BIOFIRE® FILMARRAY® Pneumonia Panel and the CE-Mark of the BIOFIRE® FILMARRAY® Pneumonia Panel plus. The BIOFIRE®  FILMARRAY®Pneumonia Panels aid in the diagnosis of lower respiratory tract infections. bioMérieux’s molecular biology affiliate, BioFire Diagnostics, builds upon its... Read more

bioMérieux acquires a majority stake in Hybiome and strengthens its presence both in China and in the immunoassay market

09 November, 2018 bioMérieux, a world leader in the field of in vitro diagnostics, today announces the acquisition of a majority holding in Suzhou Hybiome Biomedical Engineering Co.Ltd. This announcement follows the acquisition of a minority stake in July 2018. Founded in 2009 and based in Suzhou (China), Hybiome is specialized in automated immunoassay tests. The... Read more

Business review for the nine months ended September 30, 2018

18 October, 2018 Strong sales dynamic confirmed in third quarter, with an 8.8% increase in organic sales Growth of 9.8% at constant exchange rates and scope of consolidation over the nine months ended September 30: €1,749 million in sales Up 4.5% as reported Ramp-up in business on the back of three key growth drivers: molecular... Read more

Quanterix Announces Termination of License Agreement With Biomérieux

Secures and Consolidates Unrestricted Rights for Simoa Technology in Diagnostics Market LEXINGTON, Mass.–(BUSINESS WIRE)–Sep. 12, 2018– Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the consolidation of its licensing position and reestablishment of control of its intellectual property in the in vitro diagnostics (IVD) field. The termination... Read more

bioMérieux launches ENDOZYME® II GO, an innovative test for the detection of endotoxins in pharmaceutical microbiology control

01 June, 2018 bioMérieux, a world leader in the field of industrial microbiological control, announces the launch of ENDOZYME® II GO, a new endotoxin test in the bioMérieux ENDONEXTTM range of recombinant horseshoe crab Factor C (rFC) assays. This new assay resulting from the combined expertise of bioMérieux in microbiology and Hyglos GmbH in endotoxin detection enables... Read more